Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 61 to 75 of 101 results for schizophrenia

  1. Anxiety disorders (QS53)

    This quality standard covers identifying and managing anxiety disorders in adults, young people and children in primary, secondary and community care. It covers a range of anxiety disorders, including generalised anxiety disorder, social anxiety disorder, post-traumatic stress disorder, panic disorder, obsessive-compulsive disorder and body dysmorphic disorder. It describes high-quality care in priority areas for improvement.

  2. Coexisting severe mental illness and substance misuse: community health and social care services (NG58)

    This guideline covers how to improve services for people aged 14 and above who have been diagnosed as having coexisting severe mental illness and substance misuse. The aim is to provide a range of coordinated services that address people’s wider health and social care needs, as well as other issues such as employment and housing.

  3. Learning disability: identifying and managing mental health problems (QS142)

    This quality standard covers the prevention, assessment and management of mental health problems in people with learning disabilities in all settings (including health, social care, education, and forensic and criminal justice). It also covers family members, carers and care workers.

  4. What is the impact of coexisting physical health conditions on the mortality of people with complex psychosis?

    antipsychotic medicines recommended in the NICE guidelines on psychosis and schizophrenia in adults and bipolar disorder should form the...

  5. What is the clinical and cost effectiveness for family intervention combined with individual CBT in the treatment of children and young people considered to be at high risk of developing psychosis and their parents or carers?

    Source guidance details Comes from guidance Psychosis and schizophrenia in children and young people: recognition and management Number

  6. What is the clinical and cost effectiveness of omega-3 fatty acids in the treatment of children and young people considered to be at high risk of developing psychosis?

    Source guidance details Comes from guidance Psychosis and schizophrenia in children and young people: recognition and management Number

  7. The physical health benefits of discontinuing antipsychotic medication:- What are the short- and long-term benefits to physical health of guided medication discontinuation and/or reduction in first episode psychosis and can this be achieved without major risks?

    Source guidance details Comes from guidance Psychosis and schizophrenia in adults: prevention and management Number CG178 Date

  8. Maintaining the benefits of early intervention in psychosis services after discharge:- How can the benefits of early intervention in psychosis services be maintained once service users are discharged after 3 years?

    Source guidance details Comes from guidance Psychosis and schizophrenia in adults: prevention and management Number CG178 Date

  9. Aripiprazole for treating moderate to severe manic episodes in adolescents with bipolar I disorder (TA292)

    Evidence-based recommendations on aripiprazole for treating moderate to severe manic episodes in young people with bipolar I disorder.

  10. Autism spectrum disorder in under 19s: recognition, referral and diagnosis (CG128)

    This guideline covers recognising and diagnosing autism spectrum disorder in children and young people from birth up to 19 years. It also covers referral. It aims to improve the experience of children, young people and those who care for them.

  11. KardiaMobile 6L for measuring cardiac QT interval in adults having antipsychotic medication: early value assessment (HTE10)

    Early value assessment (EVA) guidance on KardiaMobile 6L for measuring cardiac QT interval in adults having antipsychotic medication....

  12. Schizophrenia (CG1)

    This guidance has been updated and replaced by NICE guideline CG82.

  13. Schizophrenia: lurasidone (ESNM15)

    This evidence summary has been replaced by ESNM48

  14. Bipolar disorder in adults (QS95)

    This quality standard covers recognising, assessing and managing bipolar disorder in adults (aged 18 and over) in primary and secondary care. It describes high-quality care in priority areas for improvement.